ASX - By Stock
|
PAB |
Re:
Ann: Further update on PAT-DX1 GMP manufacturing run
|
|
salty74
|
103 |
30K |
4 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
103
|
30K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Further update on PAT-DX1 GMP manufacturing run
|
|
salty74
|
103 |
30K |
4 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
103
|
30K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Further update on PAT-DX1 GMP manufacturing run
|
|
salty74
|
103 |
30K |
4 |
29/07/24 |
29/07/24 |
ASX - By Stock
|
103
|
30K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 June 2024
|
|
salty74
|
18 |
4.9K |
6 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
18
|
4.9K
|
6
|
|
ASX - By Stock
|
PAB |
Re:
M & A Activities
|
|
salty74
|
13 |
5.4K |
8 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
13
|
5.4K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Update on GMP manufacturing run of PAT-DX1
|
|
salty74
|
10 |
6.8K |
9 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
10
|
6.8K
|
9
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Update on GMP manufacturing run of PAT-DX1
|
|
salty74
|
10 |
6.8K |
2 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
10
|
6.8K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Positive preclinical data for deoxymabs in vasculitis
|
|
salty74
|
60 |
24K |
3 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
60
|
24K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Positive preclinical data for deoxymabs in vasculitis
|
|
salty74
|
60 |
24K |
6 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
60
|
24K
|
6
|
|
ASX - By Stock
|
PAB |
Re:
M & A Activities
|
|
salty74
|
13 |
5.4K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
13
|
5.4K
|
4
|
|
ASX - By Stock
|
BML |
Re:
Silver + lead
|
|
salty74
|
130 |
36K |
3 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
130
|
36K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Positive preclinical data for deoxymabs in vasculitis
|
|
salty74
|
60 |
24K |
2 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
60
|
24K
|
2
|
|
ASX - By Stock
|
BML |
Re:
Ann: Letter to Eligible Entitlement Offer Shareholders
|
|
salty74
|
11 |
4.0K |
5 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
11
|
4.0K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 31 March 2024
|
|
salty74
|
32 |
14K |
11 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
32
|
14K
|
11
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 31 March 2024
|
|
salty74
|
32 |
14K |
0 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
32
|
14K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
1 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
89
|
36K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
4 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
89
|
36K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Positive preclinical data for deoxymabs in vasculitis
|
|
salty74
|
60 |
24K |
8 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
60
|
24K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
2 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
89
|
36K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
1 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
89
|
36K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
89
|
36K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
1 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
89
|
36K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
89
|
36K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
89
|
36K
|
1
|
|
ASX - By Stock
|
LYC |
Re:
Interesting
|
|
salty74
|
478 |
179K |
22 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
478
|
179K
|
22
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Presentation to highlight broader potential of Deoxymabs
|
|
salty74
|
89 |
36K |
7 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
89
|
36K
|
7
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
salty74
|
10 |
4.4K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
10
|
4.4K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
salty74
|
10 |
4.4K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
10
|
4.4K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2023
|
|
salty74
|
10 |
4.4K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
10
|
4.4K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
2024 An Eventful Year
|
|
salty74
|
61 |
26K |
11 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
61
|
26K
|
11
|
|
ASX - By Stock
|
PAB |
Re:
2024 An Eventful Year
|
|
salty74
|
61 |
26K |
2 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
61
|
26K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
2024 An Eventful Year
|
|
salty74
|
61 |
26K |
5 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
61
|
26K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
2024 An Eventful Year
|
|
salty74
|
61 |
26K |
3 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
61
|
26K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Chair's Address and CEO Presentation to 2023 AGM
|
|
salty74
|
74 |
28K |
4 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
74
|
28K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
2024 An Eventful Year
|
|
salty74
|
61 |
26K |
5 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
61
|
26K
|
5
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Chair's Address and CEO Presentation to 2023 AGM
|
|
salty74
|
74 |
28K |
1 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
74
|
28K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: GMP Production of PAT-DX1 Next Quarter
|
|
salty74
|
62 |
16K |
0 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
62
|
16K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: GMP Production of PAT-DX1 Next Quarter
|
|
salty74
|
62 |
16K |
2 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
62
|
16K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: GMP Production of PAT-DX1 Next Quarter
|
|
salty74
|
62 |
16K |
0 |
16/12/23 |
16/12/23 |
ASX - By Stock
|
62
|
16K
|
0
|
|
ASX - By Stock
|
PAB |
Re:
Ann: GMP Production of PAT-DX1 Next Quarter
|
|
salty74
|
62 |
16K |
2 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
62
|
16K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: GMP Production of PAT-DX1 Next Quarter
|
|
salty74
|
62 |
16K |
9 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
62
|
16K
|
9
|
|
ASX - By Stock
|
PAB |
Re:
ADC's on the move........
|
|
salty74
|
9 |
3.0K |
3 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
9
|
3.0K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Notification of cessation of securities - PAB
|
|
salty74
|
21 |
5.3K |
1 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
21
|
5.3K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Chair's Address and CEO Presentation to 2023 AGM
|
|
salty74
|
74 |
28K |
9 |
26/11/23 |
26/11/23 |
ASX - By Stock
|
74
|
28K
|
9
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Chair's Address and CEO Presentation to 2023 AGM
|
|
salty74
|
74 |
28K |
6 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
74
|
28K
|
6
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Patrys Receives R&D Tax Incentive Refund
|
|
salty74
|
12 |
4.2K |
2 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
12
|
4.2K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Patrys Receives R&D Tax Incentive Refund
|
|
salty74
|
12 |
4.2K |
8 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
12
|
4.2K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 September 2023
|
|
salty74
|
14 |
5.7K |
4 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
14
|
5.7K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4C - Quarterly - 30 September 2023
|
|
salty74
|
14 |
5.7K |
5 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
14
|
5.7K
|
5
|
|
ASX - By Stock
|
PAB Medicine |
Re:
GENETAL
|
|
salty74
|
74 |
37K |
4 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
74
|
37K
|
4
|
|